Initiating T2D treatment with an SGLT2 inhibitor reduced risk for heart failure hospitalization compared to metformin in a new study; cardiovascular outcomes were similar.
The USPSTF is rumored to have moved screening for chronic kidney disease to a preventive service it is actively considering and the NFK says, "It's time."
Kosiborod, a cardiologist, and Skolnik, a family practitioner, agree no single specialty owns that prescription and that "it takes a village to care for a patient."
Among more than 3000 participants with prediabetes, neither metformin or lifestyle change reduced risk for CV events over 21 years according to Diabetes Prevention Program Outcomes Study investigators.
Compare, contrast, price shop, prescribe. DiabetesWise Pro developer Korey Hood, PhD, highlights the tool all primary care clinicians should try.
In adults with type 2 diabetes seen in primary care, lowering glucose substantially during the first 12 months post-diagnosis decreased risk for future MACE.
Mikhail Kosiborod, MD, a cardiologist and Neil Skolnik, MD, a primary care physician, agree that whoever is seeing the patient should prescribe the drug that is needed.
Tirzepatide, a novel once-weekly GLP-1/GIP mimetic that binds to receptors and stimulates glucose-dependent insulin release, has shown superiority over many common antihyperglycemics.
A study of the most genetically diverse collection of DNA from persons with T2D yields 40 new potentially causative genes that may transcend ancestry.
Lowering thresholds for BMI value and age of first diabetes screening among large US minority populations could greatly increase rates of diagnosis and improve care.